Almac’s expansion of its API manufacturing facility at its European Headquarters in Craigavon, UK has been completed and will be operational by the end of the year. The expansion includes the installation of two 1,000L reactors and pressure filter dryer, which allows production of GMP API to 150kg batch size.
“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development,” said Denis Geffroy, vice president of business development. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”
The expansion allows clients to leverage Almac’s API and drug product offering at the same site, allowing technology transfer of small molecule and peptide projects from lab development to large-scale manufacture.